Chinese Journal of Tissue Engineering Research ›› 2012, Vol. 16 ›› Issue (6): 1067-1070.doi: 10.3969/j.issn.1673-8225.2012.06.026

Previous Articles     Next Articles

Expression of chemokine receptor 2 mRNA in bone marrow cells of acute lymphocytic leukemia patients  

Wang Xiao-tao, Tang Rong-fang, Tang Ai-lin, Nie Yu-wei, Liu Jian, Mo Dong-hua   

  1. Department of Hematology, Affiliated Hospital of Guilin Medical College, Guilin  541001, Guangxi Zhuang Autonomous Region, China
  • Received:2011-07-03 Revised:2011-08-09 Online:2012-02-05 Published:2012-02-05
  • About author:Wang Xiao-tao★, Master, Associate chief physician, Department of Hematology, Affiliated Hospital of Guilin Medical College, Guilin 541001, Guangxi Zhuang Autonomous Region, China wxttjl@126.com
  • Supported by:

     Project of Scientific Research and Technology Development of Guilin, No. 20110119-1-12*; Health Department Planning Project of Guangxi Zhuang Autonomous Region, No. Z2011200*

PDF

698

Abstract:

BACKGROUND: In clinical practice, the expression of chemokine receptor 2 (CCL2) in bone marrow cells is hoped to be used in hazardous classification and prognosis estimation of acute lymphocytic leukemia patients.
OBJECTIVE: To investigate the expression of CCL2 mRNA in bone marrow cells of patients with acute lymphocytic leukemia.
METHODS: Fifty patients with newly diagnosed ALL were selected as experimental group, and thirty patients without hematological tumor were taken as control group. After treatment, the experimental group was divided into complete remission (CR) group (43 cases) and incomplete remission group (7 cases) according to the efficacy. 5 mL bone marrow from each case was extracted in order to detect the CCL2 mRNA expression by semi-quantitative polymerase chain reaction. 
RESULTS AND CONCLUSION: CCL2 mRNA expression in the experimental group was significantly higher than that in the  control group (P < 0.05). CCL2 mRNA expression in the CR group was significantly lower than that in the incomplete remission group (P < 0.01). CCL2 mRNA expression in the CR group after treatment was decreased than before (P < 0.01). CCL2 mRNA expression in the incomplete remission group before treatment was not obviously decreased compared with that after 2 courses of treatment (P > 0.05). CCL2 mRNA expression in acute lymphocytic leukemia patients with immune subtype pre-B was higher than with immune subtype common B and T (P < 0.05). CCL2 mRNA expression in patients with white blood cells≥50×109/L was higher than patients with white blood cells <10×109/L and 10×109/L≤ white blood cells < 50×109/L (P < 0.05), the 10×109/L≤ white blood cells < 50×109/L group was higher than the white blood cells < 10×109/L group (P < 0.01). It is indicated that the bone marrow of acute lymphocytic leukemia patients can secrete out CCL2, bone marrow levels of CCL2 mRNA are related to the count of white blood cells at diagrosis and the immune subtype. The levels of CCL2 mRNA can reflect the short short-term outcomes in some degree.

CLC Number: